
Thermo Fisher Scientific Inc.
NYSE•TMO
CEO: Mr. Marc N. Casper
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1980-03-17
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Contact Information
Market Cap
$234.50B
P/E (TTM)
35.6
38.2
Dividend Yield
0.3%
52W High
$629.87
52W Low
$385.46
52W Range
Rank21Top 7.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$11.12B+4.94%
4-Quarter Trend
EPS
$4.28+0.23%
4-Quarter Trend
FCF
$1.84B-3.12%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Revenue Growth Total revenues $32.34B USD (9M), reporting 3% growth; organic revenue growth reached 2% for the nine months.
Earnings Per Share Increase GAAP diluted EPS $12.53 USD (9M), showing 7% increase; adjusted EPS $16.30 USD, up 3% for nine months.
Life Sciences Segment Strength Life Sciences Solutions revenue $7.43B USD (9M), grew 6% reported, led by bioproduction business growth.
Balance Sheet Expansion Total assets grew to $103.02B USD from $97.32B USD since year-end 2024, reflecting recent acquisitions.
Risk Factors
Restructuring Charge Execution $316M restructuring charges recorded for workforce reductions and facility consolidations; further charges expected in 2025/2026.
Market Demand Softness Academic/government market revenue declined due to customer hesitancy; uncertain environment impacting equipment and instrument demand.
Cash Position Reduction Cash, equivalents, and restricted cash decreased to $2.01B USD from $4.04B USD at December 31, 2024.
Litigation Outcome Uncertainty Possible unfavorable litigation outcomes could materially affect financial position and results of operations if realized.
Outlook
Pending Clario Acquisition Agreement reached to acquire Clario for ~$8.88B cash, expected to close by mid-2026, joining LPS segment.
Growth Strategy Execution Strategy execution focuses on high-impact innovation, leveraging trusted partner status and unparalleled commercial engine.
Capital Deployment Priorities Capital deployment prioritized for mergers and acquisitions, followed by share buybacks and dividend payments.
Future Restructuring Costs Expecting additional restructuring charges of ~$140M, primarily in 2025 and 2026, related to identified actions.
Peer Comparison
Revenue (TTM)
MRK$64.24B
NVS$56.37B
ABT$43.84B
Gross Margin (Latest Quarter)
MRK81.9%
NVS75.4%
AMGN67.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NVS | $276.96B | 19.5 | 34.1% | 29.8% |
| MRK | $271.83B | 14.3 | 38.9% | 31.9% |
| TMO | $234.50B | 35.6 | 13.1% | 34.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.8%
Flat Growth
4Q Net Income CAGR
-4.1%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Jan 29, 2026
EPS:$6.43
|Revenue:$11.88B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 27, 2025|Filed: Oct 31, 2025|Revenue: $11.12B+4.9%|EPS: $4.28+0.2%MissForm 10-Q - Q2 2025
Period End: Jun 28, 2025|Filed: Aug 1, 2025|Revenue: $10.86B+3.0%|EPS: $4.28+5.7%MissForm 10-Q - Q1 2025
Period End: Mar 29, 2025|Filed: May 2, 2025|Revenue: $10.36B+0.2%|EPS: $3.99+14.7%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 20, 2025|Revenue: $42.88B+0.1%|EPS: $16.58+6.8%MissForm 10-Q - Q3 2024
Period End: Sep 28, 2024|Filed: Nov 1, 2024|Revenue: $10.60B+0.2%|EPS: $4.27-3.8%MissForm 10-Q - Q2 2024
Period End: Jun 29, 2024|Filed: Aug 2, 2024|Revenue: $10.54B-1.4%|EPS: $4.05+14.7%MissForm 10-Q - Q1 2024
Period End: Mar 30, 2024|Filed: May 3, 2024|Revenue: $10.35B-3.4%|EPS: $3.48+4.2%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 22, 2024|Revenue: $42.86B-4.6%|EPS: $15.53-12.4%Miss